 A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF A 12-WEEK COMBINATION THERAPY OF TMC647055 AND TMC435 WITH AND WITHOUT GSK23336805 WITH A PHARMACOKINETIC ENHANCER WITH AND WITHOUT RIBAVIRIN IN PATIENTS INFECTED WITH CHRONIC GENOTYPE 1 HEPATITIS C VIRUS: 